

# Ingrid Pabinger

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6069935/ingrid-pabinger-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

204  
papers

8,418  
citations

47  
h-index

87  
g-index

218  
ext. papers

10,166  
ext. citations

6.1  
avg, IF

6.1  
L-index

#	Paper	IF	Citations
204	Recombinant single-chain factor VIII in severe hemophilia: Long-term safety and efficacy in previously treated patients in the AFFINITY extension study.. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2022</b> , 6, e12665	5.1	0
203	Cancer-associated venous thromboembolism.. <i>Nature Reviews Disease Primers</i> , <b>2022</b> , 8, 11	51.1	9
202	Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: A systematic review. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> ,	15.4	2
201	Impact of ABO Blood Group Type on Risk of Venous Thromboembolism in Patients with Cancer. <i>Blood</i> , <b>2021</b> , 138, 2119-2119	2.2	
200	Renal Function and Risk of Arterial Thrombotic Events in Patients Positive for Lupus Anticoagulant. <i>Blood</i> , <b>2021</b> , 138, 290-290	2.2	
199	Thrombomodulin in patients with mild to moderate bleeding tendency. <i>Haemophilia</i> , <b>2021</b> , 27, 1028-1036	3.3	0
198	Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. <i>Thrombosis Research</i> , <b>2021</b> , 207, 126-130	8.2	5
197	Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis. <i>European Heart Journal</i> , <b>2021</b> , 42, 2299-2307	9.5	19
196	Natural IgM antibodies inhibit microvesicle-driven coagulation and thrombosis. <i>Blood</i> , <b>2021</b> , 137, 1406-1415	11.5	7
195	Extracellular Vesicle-Associated Tissue Factor Activity in Prostate Cancer Patients with Disseminated Intravascular Coagulation. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
194	Pain management in hemophilia: expert recommendations. <i>Wiener Klinische Wochenschrift</i> , <b>2021</b> , 133, 1042-1056	2.3	5
193	Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study. <i>Haemophilia</i> , <b>2021</b> , 27, e347-e356	3.3	3
192	Fibrinolysis and bleeding of unknown cause. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, e12511	5.1	1
191	ELISA detection of MPO-DNA complexes in human plasma is error-prone and yields limited information on neutrophil extracellular traps formed in vivo. <i>PLoS ONE</i> , <b>2021</b> , 16, e0250265	3.7	7
190	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. <i>Thrombosis and Haemostasis</i> , <b>2021</b> ,	7	1
189	Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability. <i>Cancers</i> , <b>2021</b> , 13,	6.6	7
188	Growth differentiation factor-15 predicts major adverse cardiac events and all-cause mortality in patients with atrial fibrillation. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 88, 35-42	3.9	4

187	Natural anticoagulants: A missing link in mild to moderate bleeding tendencies. <i>Haemophilia</i> , <b>2021</b> , 27, 701-709	3.3	3
186	Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria. <i>Scientific Reports</i> , <b>2021</b> , 11, 12967	4.9	1
185	Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 1819-1822	15.4	66
184	Alternative activation of human macrophages enhances tissue factor expression and production of extracellular vesicles. <i>Haematologica</i> , <b>2021</b> , 106, 454-463	6.6	8
183	Neutrophil subpopulations and their activation potential in patients with antiphospholipid syndrome and healthy individuals. <i>Rheumatology</i> , <b>2021</b> , 60, 1687-1699	3.9	5
182	Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. <i>Blood</i> , <b>2021</b> , 137, 1669-1678	2.2	44
181	Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 654-663	15.4	4
180	Limitations of a calibrated, quantitative APC-R assay under routine conditions. <i>International Journal of Laboratory Hematology</i> , <b>2021</b> , 43, 318-323	2.5	3
179	Low molecular weight heparin use in COVID-19 is associated with curtailed viral persistence-a retrospective multicenter observational study. <i>Cardiovascular Research</i> , <b>2021</b> ,	9.9	6
178	Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer. <i>Blood Advances</i> , <b>2021</b> , 5, 487-495	7.8	8
177	Lower physical activity and altered body composition in patients with haemophilia compared with healthy controls. <i>Haemophilia</i> , <b>2021</b> , 27, e260-e266	3.3	2
176	The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients. <i>Scientific Reports</i> , <b>2021</b> , 11, 3092	4.9	5
175	Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery. <i>Haemophilia</i> , <b>2021</b> , 27, e331-e339	3.3	1
174	Histone citrullination as a novel biomarker and target to inhibit progression of abdominal aortic aneurysms. <i>Translational Research</i> , <b>2021</b> , 233, 32-46	11	8
173	Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2984-2996	15.4	0
172	Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2021</b> , 41, 2837-2847	9.4	2
171	Risk assessment models of cancer-associated thrombosis - Potentials and perspectives. <i>Thrombosis Update</i> , <b>2021</b> , 5, 100075	0.9	2
170	Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency. <i>Blood Advances</i> , <b>2021</b> , 5, 391-398	7.8	7

169	Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	11
168	Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 550-561	5.1	31
167	Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027. <i>Haemophilia</i> , <b>2020</b> , 26, e201-e204	3.3	2
166	Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non-severe haemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 1081-1086	15.4	7
165	Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: A prospective study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 1348-1356	15.4	19
164	Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysis. <i>Atherosclerosis</i> , <b>2020</b> , 298, 1-6	3.1	6
163	Altered platelet proteome in lupus anticoagulant (LA)-positive patients-protein disulfide isomerase and NETosis as new players in LA-related thrombosis. <i>Experimental and Molecular Medicine</i> , <b>2020</b> , 52, 66-78	12.8	7
162	The discriminatory power of bleeding assessment tools in adult patients with a mild to moderate bleeding tendency. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 78, 34-40	3.9	9
161	Association of ABO Blood Group with Bleeding Severity in Patients with Bleeding of Unknown Cause. <i>Blood</i> , <b>2020</b> , 136, 16-18	2.2	
160	Biomarkers of Haemostasis and Occurrence of Venous Thromboembolism Are Associated with Disease Progression and Poor Prognosis in Patients with Pancreatic Cancer. <i>Blood</i> , <b>2020</b> , 136, 7-8	2.2	
159	Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma. <i>ESMO Open</i> , <b>2020</b> , 5, e000647	6	1
158	Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 277-288	7	7
157	Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer. <i>Thrombosis Research</i> , <b>2020</b> , 187, 9-17	8.2	7
156	3D gait analysis, haemophilia joint health score, leg muscle laterality and biomarkers of joint damage: A cross-sectional comparative assessment of haemophilic arthropathy. <i>Haemophilia</i> , <b>2020</b> , 26, e323-e333	3.3	5
155	Prevention of venous thromboembolism in ambulatory patients with cancer. <i>ESMO Open</i> , <b>2020</b> , 5, e000948	9.8	9
154	Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future. <i>Thrombosis Research</i> , <b>2020</b> , 191 Suppl 1, S3-S11	8.2	11
153	Longitudinal analysis of extracellular vesicle-associated tissue factor activity in cancer patients. <i>Thrombosis Research</i> , <b>2020</b> , 195, 215-218	8.2	2
152	Association of ABO blood group with bleeding severity in patients with bleeding of unknown cause. <i>Blood Advances</i> , <b>2020</b> , 4, 5157-5164	7.8	9

151	Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting. <i>Annals of Hematology</i> , <b>2020</b> , 99, 2763-2771	3	6
150	Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
149	How I treat cancer-associated thrombosis. <i>ESMO Open</i> , <b>2020</b> , 5, e000610	6	13
148	Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death. <i>Translational Research</i> , <b>2020</b> , 215, 41-56	11	4
147	Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. <i>Haemophilia</i> , <b>2020</b> , 26, 494-502	3.3	22
146	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , <b>2019</b> , 20, e566-e581	21.7	264
145	Thrombin-generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1478-1488	15.4	15
144	The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2019</b> , 3, 503-514	5.1	16
143	Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. <i>Blood</i> , <b>2019</b> , 134, 2082-2091	2.2	70
142	Association of complete blood count parameters, d-dimer, and soluble P-selectin with risk of arterial thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1335-1344	15.4	15
141	Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer. <i>British Journal of Haematology</i> , <b>2019</b> , 186, 311-320	4.5	49
140	The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1772-1778	15.4	62
139	Increased Citrullinated Histone H3 Levels in the Early Post-Resuscitative Period Are Associated with Poor Neurologic Function in Cardiac Arrest Survivors-A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	4
138	BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results. <i>Haemophilia</i> , <b>2019</b> , 25, 1011-1019	3.3	18
137	Factor VIII Levels in Blood Group O and Non-O in Patients with Non-Severe Haemophilia a. <i>Blood</i> , <b>2019</b> , 134, 1135-1135	2.2	
136	Epidemiology and Treatment of Patients with Haemophilia in Austria-Update from the Austrian Haemophilia Registry. <i>Hamostaseologie</i> , <b>2019</b> , 39, 284-293	1.9	4
135	How I treat patients with hereditary antithrombin deficiency. <i>Blood</i> , <b>2019</b> , 134, 2346-2353	2.2	8
134	High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant. <i>Blood Advances</i> , <b>2019</b> , 3, 769-776	7.8	8

133	Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma. <i>Cancers</i> , <b>2019</b> , 11,	6.6	5
132	Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report. <i>HemaSphere</i> , <b>2019</b> , 3, e286	0.3	23
131	Low extracellular vesicle-associated tissue factor activity in patients with persistent lupus anticoagulant and a history of thrombosis. <i>Annals of Hematology</i> , <b>2019</b> , 98, 313-319	3	2
130	Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation. <i>Clinical and Experimental Medicine</i> , <b>2018</b> , 18, 325-336	4.9	16
129	The role of podoplanin in cancer-associated thrombosis. <i>Thrombosis Research</i> , <b>2018</b> , 164 Suppl 1, S34-S38.	2	29
128	Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). <i>Oncologist</i> , <b>2018</b> , 23, 247-255	5.7	42
127	Non-vitaminK antagonist oral anticoagulants in patients with an increased risk of bleeding. <i>Wiener Klinische Wochenschrift</i> , <b>2018</b> , 130, 722-734	2.3	1
126	A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. <i>Lancet Haematology</i> , <b>2018</b> , 5, e289-e298	14.6	134
125	Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension. <i>Blood</i> , <b>2018</b> , 132, 1206-1206	2.2	2
124	The Role of Neutrophil Extracellular Traps in Cancer-Associated Arterial Thrombosis. <i>Blood</i> , <b>2018</b> , 132, 2508-2508	2.2	
123	Neutrophil-Mediated Proteolysis of Thrombospondin-1 Promotes Platelet Adhesion and String Formation. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 2074-2085	7	12
122	Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 1875-1884	7	22
121	Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. <i>Haematologica</i> , <b>2018</b> , 103, 1549-1556	6.6	51
120	A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability. <i>Clinical and Experimental Medicine</i> , <b>2017</b> , 17, 251-256	4.9	10
119	Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause. <i>Annals of Hematology</i> , <b>2017</b> , 96, 489-495	3	14
118	Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. <i>Blood</i> , <b>2017</b> , 129, 1831-1839	2.2	109
117	Procoagulant extracellular vesicles in amniotic fluid. <i>Translational Research</i> , <b>2017</b> , 184, 12-20.e1	11	12
116	Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis. <i>Wiener Klinische Wochenschrift</i> , <b>2017</b> , 129, 303-316	2.3	66

115	Platelets and hemophilia: A review of the literature. <i>Thrombosis Research</i> , <b>2017</b> , 155, 131-139	8.2	8
114	Women with homozygous AT deficiency type II heparin-binding site (HBS) are at high risk of pregnancy loss and pregnancy complications. <i>Annals of Hematology</i> , <b>2017</b> , 96, 1023-1031	3	17
113	Homozygous antithrombin deficiency type II causing neonatal thrombosis. <i>Thrombosis Research</i> , <b>2017</b> , 158, 134-137	8.2	5
112	Is oral all-trans retinoic acid plus danazol a refinement of second-line therapy for primary immune thrombocytopenia in adults?. <i>Lancet Haematology,the</i> , <b>2017</b> , 4, e457-e458	14.6	2
111	Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study. <i>JNCI Cancer Spectrum</i> , <b>2017</b> , 1, pkx009	4.6	2
110	Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on maintenance hemodialysis: Cross-sectional results of the Vienna InVestigation of Atrial fibrillation and thromboembolism in patients on hemoDialysis (VIVALDI). <i>Thrombosis Research</i> , <b>2017</b> , 158, 53-61	8.2	9
109	Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant. <i>BMC Medicine</i> , <b>2017</b> , 15, 54	11.4	18
108	Cancer-associated venous thromboembolism: Burden, mechanisms, and management. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 219-230	7	208
107	Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 90-98	7	27
106	Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism?. <i>Hematology American Society of Hematology Education Program</i> , <b>2017</b> , 2017, 136-143	3.1	2
105	Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of Atrial Fibrillation and Thromboembolism in Patients on HemoDialysis (VIVALDI). <i>PLoS ONE</i> , <b>2017</b> , 12, e0169400	3.7	36
104	Testing lupus anticoagulants in a real-life scenario - a retrospective cohort study. <i>Biochimica Medica</i> , <b>2017</b> , 27, 030705	2.5	2
103	Peripheral blood microvesicles secretion is influenced by storage time, temperature, and anticoagulants. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , <b>2016</b> , 89, 663-72	4.6	57
102	Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. <i>Thrombosis Research</i> , <b>2016</b> , 144, 62-8	8.2	33
101	Alterations of blood coagulation in controlled human malaria infection. <i>Malaria Journal</i> , <b>2016</b> , 15, 15	3.6	20
100	Association of platelet activation markers with cancer-associated venous thromboembolism. <i>Platelets</i> , <b>2016</b> , 27, 80-5	3.6	30
99	Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS). <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 200-6	12.9	29
98	Predictors of Venous Thromboembolism in Colorectal Cancer: Results from a Global Prospective Study. <i>Blood</i> , <b>2016</b> , 128, 1422-1422	2.2	1

97	Global prospective cohort study of factors associated with early mortality in patients with lung cancer undergoing chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9078-9078	2.2	
96	Expectations and Concerns Towards New Extended Half-Life (EHL) Products - Results of Surveys Among Haemophilia Patients from the Dach Region. <i>Blood</i> , <b>2016</b> , 128, 4740-4740	2.2	
95	Global Prospective Cohort Study of Factors Associated with Venous Thromboembolism in Patients with Lung Cancer Receiving Cancer Therapy. <i>Blood</i> , <b>2016</b> , 128, 3590-3590	2.2	
94	Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry. <i>BMC Cardiovascular Disorders</i> , <b>2016</b> , 16, 254	2.3	16
93	Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients. <i>Oncologist</i> , <b>2016</b> , 21, 252-7	5.7	43
92	Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. <i>Blood</i> , <b>2016</b> , 127, 1761-9	2.2	134
91	Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. <i>Blood</i> , <b>2016</b> , 128, 630-7	2.2	59
90	International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , <b>2016</b> , 17, e452-e466	21.7	252
89	Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. <i>Thrombosis Research</i> , <b>2015</b> , 136, 582-9	8.2	145
88	An international, multicenter, prospective study of a prothrombin complex concentrate, Prothromplex Total $\square$ , in anticoagulant reversal. <i>Thrombosis Research</i> , <b>2015</b> , 135, 485-91	8.2	9
87	Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). <i>Blood</i> , <b>2015</b> , 125, 3477-83	2.2	44
86	Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients. <i>Thrombosis Research</i> , <b>2015</b> , 136, 865-9	8.2	13
85	Clinical-Pathological Conference Series from the Medical University of Graz Case No 155: 26-year-old woman in third trimester of pregnancy with epigastric pain and thrombocytopenia. <i>Wiener Klinische Wochenschrift</i> , <b>2015</b> , 127, 707-14	2.3	1
84	Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 1268-76	7	71
83	Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art. <i>Frontiers in Cardiovascular Medicine</i> , <b>2015</b> , 2, 30	5.4	22
82	Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year. <i>Thrombosis Research</i> , <b>2014</b> , 134, 1093-6	8.2	14
81	Statins are associated with low risk of venous thromboembolism in patients with cancer: a prospective and observational cohort study. <i>Thrombosis Research</i> , <b>2014</b> , 134, 1008-13	8.2	22
80	Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation. <i>Translational Research</i> , <b>2014</b> , 163, 145-50	11	36



79	Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). <i>Thrombosis Research</i> , <b>2014</b> , 133 Suppl 2, S39-43	8.2	52
78	Comment on Ferroni et al.: "Impact of chemotherapy on venous thromboembolism.: Comment to: Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study" HAEMATOL/2012/073338 and HAEMATOL/2013/092528. <i>Haematologica</i> , <b>2014</b> , 99, e28-9	6.6	
77	Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. <i>Blood</i> , <b>2014</b> , 123, 317-25		331
76	Red cell distribution width and other red blood cell parameters in patients with cancer: association with risk of venous thromboembolism and mortality. <i>PLoS ONE</i> , <b>2014</b> , 9, e111440	3.7	50
75	Flamethrowers: blood cells and cancer thrombosis risk. <i>Hematology American Society of Hematology Education Program</i> , <b>2014</b> , 2014, 410-417	3.1	
74	Oral anticoagulation with rivaroxaban during pregnancy: a case report. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 1323-4	7	24
73	Immune-mediated disorders causing bleeding or thrombosis in lymphoproliferative diseases. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2014</b> , 40, 359-70	5.3	9
72	Flamethrowers: blood cells and cancer thrombosis risk. <i>Hematology American Society of Hematology Education Program</i> , <b>2014</b> , 2014, 410-7	3.1	22
71	Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 1645-51	1	45
70	Association between the metabolic syndrome, its individual components, and unprovoked venous thromboembolism: results of a patient-level meta-analysis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2014</b> , 34, 2478-85	9.4	40
69	Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS). <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 670-8	7	74
68	Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. <i>Thrombosis Research</i> , <b>2014</b> , 134, 44-9	8.2	20
67	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. <i>Blood</i> , <b>2014</b> , 124, 2859-2859	2.2	2
66	Implementing thrombosis guidelines in cancer patients: a review. <i>Rambam Maimonides Medical Journal</i> , <b>2014</b> , 5, e0041	1.8	8
65	Predictors of early mortality in colorectal cancer patients undergoing chemotherapy: Results from a global prospective cohort study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 532-532	2.2	
64	Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. <i>European Journal of Clinical Investigation</i> , <b>2013</b> , 43, 277-85	4.6	47
63	Biomarkers for prediction of venous thromboembolism in cancer. <i>Blood</i> , <b>2013</b> , 122, 2011-8	2.2	174
62	Response to antiplatelet therapy is independent of endogenous thrombin generation potential. <i>Thrombosis Research</i> , <b>2013</b> , 132, e24-30	8.2	7

61	Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. <i>Haematologica</i> , <b>2013</b> , 98, 1309-14	6.6	43
60	Post-surgical hemorrhagic infarction of the adrenal gland as the first clinical manifestation of antiphospholipid syndrome after 43 years of antibody-positivity. <i>Modern Rheumatology</i> , <b>2013</b> , 23, 1237-1241	3.3	1
59	The influence of thrombophilia on the long-term survival of patients with a history of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 79-84	7	12
58	Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease. <i>European Journal of Clinical Investigation</i> , <b>2012</b> , 42, 470-7	4.6	21
57	Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. <i>Thrombosis Research</i> , <b>2012</b> , 129 Suppl 1, S6-9	8.2	32
56	Association of elevated soluble P-selectin levels with fetal loss in women with a history of venous thromboembolism. <i>Thrombosis Research</i> , <b>2012</b> , 129, 725-8	8.2	4
55	Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3870-5	2.2	84
54	High D-dimer levels are associated with poor prognosis in cancer patients. <i>Haematologica</i> , <b>2012</b> , 97, 1158-64	2.2	212
53	The role of fibrinogen plasma levels, the -455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 908-13	7	25
52	Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2099-103	2.2	162
51	Circulating procoagulant microparticles in cancer patients. <i>Annals of Hematology</i> , <b>2011</b> , 90, 447-53	3	61
50	Long-term survival of patients with a history of venous thromboembolism. <i>Annals of Hematology</i> , <b>2011</b> , 90, 585-94	3	13
49	Thrombin generation in patients with a bleeding tendency of unknown origin. <i>Annals of Hematology</i> , <b>2011</b> , 90, 1099-104	3	15
48	Decreased ADAMTS13 Activity Levels in Patients with a Bleeding Tendency of Unknown Origin. <i>Blood</i> , <b>2011</b> , 118, 1218-1218	2.2	1
47	Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP). <i>Blood</i> , <b>2011</b> , 118, 3282-3282	2.2	
46	Romiplostim or standard of care in patients with immune thrombocytopenia. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1889-99	59.2	313
45	Long-term survival after venous thromboembolism: a retrospective selected cohort study among young women. <i>Haematologica</i> , <b>2010</b> , 95, 1425-8	6.6	5
44	Prediction of venous thromboembolism in cancer patients. <i>Blood</i> , <b>2010</b> , 116, 5377-82	2.2	508

43	Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal. <i>Annals of Hematology</i> , <b>2010</b> , 89, 309-16	3	47
42	Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate. <i>Annals of Hematology</i> , <b>2010</b> , 89, 1185-95	3	21
41	Biomarkers and venous thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2009</b> , 29, 332-6	9.4	115
40	D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4124-9	2.2	281
39	Austrian Hemophilia Registry: design, development and set of variables. <i>Wiener Klinische Wochenschrift</i> , <b>2009</b> , 121, 196-201	2.3	7
38	Circulating procoagulant microparticles in patients with venous thromboembolism. <i>Thrombosis Research</i> , <b>2009</b> , 123, 724-6	8.2	45
37	Thrombophilia and its impact on pregnancy. <i>Thrombosis Research</i> , <b>2009</b> , 123 Suppl 3, S16-21	8.2	42
36	Anti-factor xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis. <i>Obstetrics and Gynecology</i> , <b>2009</b> , 113, 740	4.9	3
35	Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.. <i>Blood</i> , <b>2009</b> , 114, 679-679	2.2	2
34	High Soluble P-Selectin and Low Platelet Count as Thrombosis Risk Markers in Glioma Patients.. <i>Blood</i> , <b>2009</b> , 114, 2985-2985	2.2	
33	Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 844S-886S	5.3	603
32	High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). <i>Blood</i> , <b>2008</b> , 112, 2703-8	2.2	298
31	Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients. <i>Thrombosis and Haemostasis</i> , <b>2008</b> , 100, 217-223	7	53
30	P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2008</b> , 99, 899-904	7	27
29	Monitoring of ADAMTS13 in Patients with Thrombotic Thrombocytopenic Purpura: Prediction of Response to Therapy, Risk of Relapse, and Long- Term Outcome.. <i>Blood</i> , <b>2008</b> , 112, 2291-2291	2.2	2
28	Association of Elevated Soluble P-Selectin Levels and Fetal Loss in Women with a History of Venous Thromboembolism.. <i>Blood</i> , <b>2008</b> , 112, 1809-1809	2.2	
27	Predictive Value of D-Dimer Levels for Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS). <i>Blood</i> , <b>2008</b> , 112, 3824-3824	2.2	
26	Thrombophilia and its impact on pregnancy. <i>Hamostaseologie</i> , <b>2008</b> , 28, 130-4	1.9	2

25	Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients. <i>Thrombosis and Haemostasis</i> , <b>2008</b> , 100, 217-23	7	23
24	High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. <i>Clinical Chemistry</i> , <b>2007</b> , 53, 1235-43	5.5	90
23	Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. <i>Thrombosis and Haemostasis</i> , <b>2007</b> , 98, 790-797	7	77
22	Venous thromboembolism and survival in patients with high-grade glioma. <i>Neuro-Oncology</i> , <b>2007</b> , 9, 89-95	1	104
21	The risk for thromboembolic disease in lupus anticoagulant patients due to pathways involving P-selectin and CD154. <i>Thrombosis and Haemostasis</i> , <b>2007</b> , 97, 573-580	7	18
20	Venous thromboembolism--a manifestation of the metabolic syndrome. <i>Haematologica</i> , <b>2007</b> , 92, 374-80.6	6.6	125
19	The clinical significance of anti-prothrombin antibodies for risk assessment of thromboembolism in patients with lupus anticoagulant. <i>Thrombosis Research</i> , <b>2007</b> , 120, 295-302	8.2	13
18	Successful outcome in a pregnant woman with homozygous antithrombin deficiency. <i>Thrombosis and Haemostasis</i> , <b>2007</b> , 98, 1377-8	7	11
17	Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. <i>Thrombosis and Haemostasis</i> , <b>2007</b> , 98, 790-7	7	31
16	Interleukin-6 and interleukin-6 promoter polymorphism (174) G>C in patients with spontaneous venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 95, 802-806	7	28
15	The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. <i>Haematologica</i> , <b>2006</b> , 91, 1041-5	6.6	64
14	Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2005</b> , 93, 488-93	7	31
13	Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. <i>Blood</i> , <b>2002</b> , 100, 1060-2	2.2	149
12	Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. <i>Critical Care Medicine</i> , <b>2002</b> , 30, 763-70	1.4	52
11	Homozygous Antithrombin Deficiency Type II (99 Leu to Phe Mutation) and Childhood Thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2001</b> , 86, 1007-1011	7	67
10	Preeclampsia and fetal loss in women with a history of venous thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2001</b> , 21, 874-9	9.4	59
9	Lupus anticoagulants: strong association with the major histocompatibility complex class II and platelet antibodies. <i>British Journal of Haematology</i> , <b>1997</b> , 98, 342-5	4.5	20
8	The Risk of Recurrent Venous Thromboembolism in Patients with and without Factor V Leiden. <i>Thrombosis and Haemostasis</i> , <b>1997</b> , 77, 624-628	7	141

7	Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft für Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1996</b> , 16, 742-8	9.4	159
6	No Increased Prevalence of the Factor V Leiden Mutation in Chronic Major Vessel Thromboembolic Pulmonary Hypertension (CTEPH). <i>Thrombosis and Haemostasis</i> , <b>1996</b> , 76, 476-477	7	25
5	(ATT) trinucleotide repeats in the antithrombin gene and their use in determining the origin of repeated mutations. <i>Human Mutation</i> , <b>1994</b> , 4, 31-41	4.7	17
4	Thrombotic Risk of Women with Hereditary Antithrombin III-, Protein C- and Protein S-Deficiency Taking Oral Contraceptive Medication. <i>Thrombosis and Haemostasis</i> , <b>1994</b> , 71, 548-552	7	83
3	Evidence for an Increased Generation of Prostacyclin in the Microvasculature and an Impairment of the Platelet $\beta$ Granule Release in Chronic Renal Failure. <i>Thrombosis and Haemostasis</i> , <b>1988</b> , 60, 205-208	7	23
2	Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. <i>American Journal of Hematology</i> , <b>1987</b> , 24, 241-5	7.1	66
1	Deficiency of fibrinogen and factor VII following treatment of severe aplastic anaemia with anti-thymocyte globulin and high-dose methylprednisolone. <i>Scandinavian Journal of Haematology</i> , <b>1985</b> , 34, 312-6		11